The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: Focus on fixed-dose combination antihypertensive therapy

Renal Failure

Volumn 18, Issue 6, 1996, Pages 813-832

  Epstein, Murray ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CLENTIAZEM; CLONIDINE; DILTIAZEM; DILTIAZEM PLUS ENALAPRIL MALEATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE PLUS FELODIPINE; FELODIPINE; FUROSEMIDE; HYDRALAZINE; LISINOPRIL; LOSARTAN POTASSIUM; NIFEDIPINE; PROPRANOLOL; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; UNCLASSIFIED DRUG; VASODILATOR AGENT; VERAPAMIL;

ANGIONEUROTIC EDEMA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG MIXTURE; FEMALE; GLOMERULONEPHRITIS; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; KIDNEY CALCIFICATION; KIDNEY FAILURE; KIDNEY HYPERTROPHY; MAJOR CLINICAL STUDY; MALE; MESANGIUM; META ANALYSIS; MICROCIRCULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0029860026     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.3109/08860229609047709     Document Type: Review

References (101)

1. U.S. Renal Data System: USRDS 1994 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, July 1994.
2. National High Blood Pressure Education Program: National High Blood Pressure Education Program working group report on hypertension and chronic renal failure. Arch Intern Med 151:1280-1287, 1991.
3. Working Group on Renovascular Hypertension: Detention, evaluation, and treatment of renovascular hypertension. Arch Intern Med 147:820-829, 1987.
4. Shulman NB, Ford CE, Hall DW et al: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from Hypertension Detection and Follow-up Program. Hypertension 13(suppl 1): 180-193, 1989.
5. Pemeger TV, Nieto FJ, Whelton PK, Klag MJ, Comstock GW, Szklo M: A prospective study of blood pressure and serum creatinine. Results from the "Clue" study and the ARIC study. J Am Med Assoc 269:488-493, 1993.
6. Rosansky SJ, Hoover DR, King L, Givson J: The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 150:2073-2076, 1990.
7. Walker GW, Neaton JD, Cutler JA, Neuwirth R, Cohen JD, for the MRFIT Research Group: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. J Am Med Assoc 268:3083-3091, 1992.
8. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996.
9. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 318:1657-1666, 1988.
10. Ritz E, Orth S, Weinreich T, Wagner J: Systemic hypertension versus intraglomerular hypertension in progression. Kidney Int 45:438-442, 1994.
11. Neuringer JR, Brenner BM: Hemodynamic theory of progressive renal disease: a 10-year update in brief review. Am J Kidney Dis 22:98-104, 1993.
12. Ihle B, Becker G, Whitworth J, Charlwood R, Kincaid-Smith P: The effect of protein restriction on the progression of renal insufficiency. N Engl J Med 321:1773-1777, 1989.
13. Klahr S, Levey A, Beck GJ et al: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease N Engl J Med 330:877-884, 1994.
14. Brenner BM, Meyer TW, HostetterTH: Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically medicated injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation and intrinsic renal disease. N Engl J Med 307:652-659, 1982.
15. Griffin KA, Picken M, Bidani AK: Radiotelemetric BP monitoring, antihypertensive and glomeruloprotection in remnant kidney model. Kidney Int 45:1010-1018, 1994.
16. Hostetter TH, Olson JL, Rennke HG et al: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 241:F85-F93, 1981.
17. Hostetter TH, Rennke HG, Brenner BM: The case for intrarenal hypertension in the initiation and progression of diabetic and other golmerulopathies. Am J Med 72:375-380, 1982.
18. Dworkin LD, Hostetter TH, Rennke HG, Brenner BM: Hemodynamic basis for glomerular injury in rats with desoxycorticosterone salt hypertension. J Clin Invest 73:1448-1461, 1984.
19. Purkerson ML, Joist JH, Yates J, Valdes A, Morrison A, Klahr S: Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc Natl Acad Sci USA 82:193-197, 1985.
20. Shimamura T, Morrison AB: A progression glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 79:95-106, 1975.
21. Benstein JA, Feiner HD, Parker M, Dworkin LD: Superiority of salt restriction over diuretics in reducing renal hypertrophy and injury in uninephrectomized SHR. Am J Physiol 258 (Renal Fluid Electrolyte Physiol 27):F1675-F1681, 1990.
22. Dworkin LD, Feiner HD: Glomerular injury in uninephrectomized spontaneously hypertensive rats: a consequence of glomerular capillary hypertension. J Clin Invest 77:797-809, 1986
23. Dworkin LD, Grosser HD, Feiner M, Ullian M, Parker M: Renal vascular effects of antihypertensive therapy in uninephrectomized SHR. Kidney Int 35:790-798, 1989.
24. Ong ACM, Fine LG: Loss of glomerular function and tubulointerstitial fibrosis: cause or effects? Kidney Int 45:345-351, 1994.
25. Fine LG, Norman JT: Renal growth responses to acute and chronic injury: routes to therapeutic intervention. J Am Soc Nephrol 2:S206-S211, 1992.
26. Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP: Hyperlipidemia and progressive renal disease. Kidney Int 39:S41-S48, 1991.
27. Diamond JR, Karnovsky MJ: A putative role of hypercholesterolemia in progressive glomerular injury. Annu Rev Med 43:83-92, 1992.
28. Keane WF: Lipids and the kidney. Kidney Int 46:910-920, 1994.
29. Klag MJ, Whelton PK, Randall B, Neaton J, Brancati FL, Stamler J: Serum cholesterol and ESRD incidence in men screened for the MRFIT (abstract). J Am Soc Nephrol 6:393, 1995.
30. Harris DCH, Hammond WS, Burke TJ, Schrier RW: Verapamil protects against progression of experimental chronic renal failure. Kidney Int 31:41-46, 1987.
31. Goligorsky MS, Chaimovits C, Rapoport J et al: Calcium metabolism in uremic nephrocalcinosis: preventive effects of verapamil. Kidney Int 27:774-779, 1985.
32. Harris DCH, Chan L, Schrier RW: Remnant kidney hypermetabolism and progression of chronic renal failure. Am J Physiol 254 (Renal Fluid Electrolyte Physiol 23):F267-F276, 1988.
33. Schrier RW, Harris DCH, Chan L, Shapiro JI, Caramelo C: Tubular hypermetabolism as a factor in the progression of chronic renal failure. Am J Kidney Dis 13:243-249, 1988.
34. Jacobson HR, Striker GE: Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. Am J Kidney Dis 25:103-106, 1995.
35. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting enzyme therapy on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993.
36. Kusek JW, Agodoa L, Greene T, Jones C, for the MDRD Study Group: Comparison of decline of GFR in Blacks versus non-Blacks in the MDRD study (abstract). J Am Soc Nephrol 4:253, 1993.
37. HOT Study, HOT Study Group, Hansson L, Zanchetti A: The Hypertension Optimal Treatment (HOT) Study: patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure 3:322-327, 1994.
38. Schrier RW, Savage S: Appropriate blood pressure control in type II diabetes (ABCD) trial: implications for complications. Am J Kidney Dis 20:653-657, 1992.
39. Forster HG, ter Wee PM, Epstein M: Videomicroscopic characterization of tissue ACE in the local control of renal hemodynamics (abstract). Am J Hypertens 8:179A, 1995.
40. Loutzenhiser R, Epstein M, Hayashi K, Horton C: Direct visualization of the effects of endothelin on the renal microvasculature. Am J Physiol 258:F61-F68, 1990.
41. Loutzenhiser R, Epstein M, Hayashi K, Takenaka T, Forster H: Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753: studies in isolated perfused hydronephrotic kidneys. Am J Hypertens 4:309S-314S, 1991.
42. Meyer TW, Anderson S, Rennke HG, Brenner BM: Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 31:752-759, 1987.
43. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986.
44. Ray PE, Aquilera G, Kopp JB, Horokoshi S, Klotman PE: Angiotensin II stimulates proliferation of human fetal mesangial cells by a receptor-mediated mechanism. J Am Soc Nephrol 1:424, 1990.
45. Orth S, Nowicki M, Wiecek A. Ritz E- Nephroprotective effect of ACE inhibitors. Drugs 46(suppl 2): 189-196, 1993.
46. Irzyniec T, Mall G, Ritz E: Effects of enalapril on compensatory glomerular growth after subtotal nephrectomy (abstract). Presented at XXVII Congress of EDTA-ERA, Rimini, Italy, 1991.
47. Ichikawa I, Harris RC: Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 40:583-596, 1991.
48. Hollenberg NK, Williams GH: Angiotensin, ACE inhibition, and the renal circulation: pathogenesis of nonmodulation in essential hypertension. Contrib Nephrol 79:1-10, 1990.
49. Hollenberg NK, Fisher NDL: Renal circulation and blockade of the renin-angiotensin system: is angiotensin-converting enzyme inhibition the last word? Hypertension 26:602-609, 1995.
50. Epstein M: Evolving concepts in the management of hypertension, Clin Cardiol 18(suppl III):III-3-III-11, 1995.
51. MacFadyen RJ, Reid JL: Angiotensin receptor antagonists as a treatment for hypertension. J Hypertens 12:1333-1338, 1994.
52. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90-766-771, 1992.
53. Epstein M, Loutzenhiser R: Potential applicability of calcium antagonists as renal protective agents. In Epstein M, Loutzenhiser R (eds), Calcium Antagonists and the Kidney, Philadelphia, Hanley & Belfus, 1990, pp 275-298.
54. Epstein M: Calcium antagonists and renal protection: current status and future perspectives. Arch Intern Med 152:1573-1584, 1992
55. Epstein M: Calcium antagonists and the kidney: implications for renal protection. In Epstein M (ed), Calcium Antagonists in Clinical Medicine. Philadelphia, Hanley & Belfus, 1992, pp 309-348.
56. Dworkin LD. Effects of calcium channel blockers on experimental glomerular injury. J Am Soc Nephrol 1:S21-S27, 1990.
57. Dworkin LD: Impact of calcium entry blockers on glomerular injury in experimental hypertension. Cardiovasc Drugs Ther 4:1325-1330, 1990.
58. Dworkin LD, Levin RI, Benstein JA et al: Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol 259:G598-F604, 1990.
59. Sweeney C, Shultz P, Raij L: Interactions of the endothelium and mesangium in glomerular injury. J Am Soc Nephrol 1:S13-S20, 1990.
60. Raij L, Keane W: Glomerular mesangium: its function and relationship to angiotensin II. Am J Med 79(suppl 36):24-30, 1985.
61. Dworkin LD, Benstein JA: Antihypertensive agents, glomerular hemodynamics and glomerular injury. In Epstein M, Loutzenhiser R (eds), Calcium Antagonists and the Kidney, Philadelphia, Hanley & Belfus, 1990, pp 155-176.
62. Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD: Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 43:808-814, 1993.
63. Keane WJ, Raij L: Relationship among altered glomerular barrier permselectivity, angiotensin II and mesangial uptake of macromolecules. Lab Invest 52:599-604, 1985.
64. Sweeney C, Raij L: Interactions of the endothelium and mesangium in glomerülar injury: potential role of calcium antagonists. In Epstein M (ed), Calcium Antagonists in Clinical Medicine, Philadelphia, Hanley & Belfus, 1992, pp 413-426.
65. Shultz P, Raij L: Inhibition of human mesangial cell proliferations by calcium blockers. Hypertension 15(suppl 1):76-80, 1990.
66. Shultz P, Raij L: Effect of amlodipine on mesangial cell proliferation and protein synthesis. Am J Hypertens 5:912-914, 1992.
67. Tolins J, Melemed A, Sulciner A, Gustafson K, Vercellotti G. Calcium channel blockade inhibits platelet activating factor production by human umbilical vein endothelial cells. Lipids 26:1218-1222, 1991.
68. Burke TJ, Singh H, Schrier RW: Calcium handling by renal tubules during oxygen deprivation injury to the kidney prior to reoxygenation. J Cardiovasc Drugs Ther 4:1319-1324, 1990.
69. Schrier RW, Burke TJ: Calcium channel-blockers in experimental and human acute renal failure. Adv Nephrol 17:287-300, 1988.
70. Schwertschlag U, Schrier RW, Wilson P: Beneficial effects of calcium channel blockers and calmodulin binding drugs on in vitro renal cell anoxia. J Pharmacol Exp Ther 238:119-124, 1986.
71. Jackson B, Johnston CI: The contribution of systemic hypertension to progression of chronic renal failure in the rat remnant kidney: effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor. J Hypertens 6:495-501, 1988.
72. Brunner FP, Thiel G, Hermle M, Bock HA, Mihatsch MJ: Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 36:969-977, 1989.
73. Tolins JP, Raij L: Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 16:452-461, 1990.
74. De Zeeuw D. Meta-analysis on non-diabetic disease blood pressure trials (abstract), Proceedings XIII Int Cong Nephrol, Madrid, Spain, July 1995, p 65.
75. Weidmann P, Schneider M, Boehlen L: Effects of different antihypertensive drugs in diabetic nephropathy: a meta-analysis (abstract). Proceedings XIII Int Cong Nephrol, Madrid, Spain, July 1995, p 66.
76. ter Wee PM, Epstein M: Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease. Arch Intern Med 153:1749-1759, 1993.
77. ter Wee P, De Micheli AG, Epstein M: Effects of calcium antagonists on renal hemodynamics and progression of non-diabetic chronic renal disease. Arch Intern Med 154:1185-1202, 1994.
78. Bauer JH, Reams GP, Lal SM: Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med 147:1397-1400, 1987.
79. Ruilope LM, Miranda B, Morales JM, Rodicio JL, Romero JC, Raij L: Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis 13:120-126, 1989.
80. Kamper AL, Strandgaard S, Leyssac PP: Effect of enalapril on the progression of chronic renal failure. a randomized controlled trial. Am J Hypertens 5:423-430, 1992.
81. Zucchelli P, Zuccalà A, Borghi M et el: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452-458, 1992.
82. Hannedouche T, Landais P, Goldfarb B, Elesper N, Fournier A, Goidin M, Durand D, Chanard J, Mignon F, Suc J-M, Grunfeld J-P: Randomized controlled trial of enalapril and β-blockers in non-diabetic chronic renal failure. Br Med J 309:833-837, 1994.
83. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155:1073-1080, 1995.
84. Anderson S: Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension 17:288-295, 1991.
85. Carmines PK, Navar LG: Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol 256:F1015-F1020, 1989.
86. Brown S, Walton C, Crawford P, Bakris GL: Long-term effects of different antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 43:1210-1218, 1993.
87. Munter K, Hergenröder S, Jochims K, Kirchengast M: Individual and combined effects of verapamil or trandolapril on glomemloprotection in the stroke prone rat. J Am Soc Nephrol 7:681-686, 1996.
88. Bakris GL, Barnhill BW, Sadler R: Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 41:912-919, 1992.
89. Fioretto P, Frigato F, Velussi M et al: Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens 5:837-846, 1992.
90. NEPHROS Study: Personal communication, M. Aurell.
91. Guazzi MD, De Cesare N, Galli C et al: Calcium-channel blockade with nifedipine and angiotensin converting-enzyme inhibition with Captopril in the therapy of patients with severe primary hypertension. Circulation 70:279-284, 1984.
92. Stornello M, Dia Rao G, Iachello M et al: Haemodynamic and humoral interactions between captopril and nifedipine. Hypertension 5(suppl III):S154-S156, 1983.
93. Morgan TO, Anderson A, Jones E: Comparison and interaction of Low dose felodipine and enalapril in the treatment of essential hypertension in elderly subject. Am J Hypertens 5:238-243, 1992.
94. Leonetti G, Gradnik R, Terzoli L, Fruscio M, Rupoli L, Cuspidi C, Sampieri L, Zanchetti A: Effects of single and repeated doses of the calcium antagonist felodipine on blood pressure, renal function, electrolytes and water balance, and renin-angiotensin-aldosterone system in hypertensive patients. J Cardiovasc Pharmacol 8:1243-1248, 1986.
95. Epstein M, De Micheli AG: Natriuretic effects of calcium antagonists. In Epstein M (ed), Calcium Antagonists in Clinical Medicine, Philadelphia, Hanley & Belfus, 1992, pp 349-366.
96. Bakris GL, Barnhill BW, Sadler R: Treatment of arterial hypertension in diabetic man: importance of therapeutic selection. Kidney Int 41:912-919, 1992.
97. Product insert for Lotrel, Ciba-Geigy, Summit NJ, 1995.
98. Gradman AH, for the Enalapril/Felodipine Factorial Study Group: Combination therapy with enalapril/ felodipine ER (EF) in essential hypertension: a factorial study. Am J Hypertens (abstract) 9:1996 (in press).
99. Gustafsson D, Grände P-O, Borgström P, Lindberg L: Effects of calcium antagonists on myogenic and neurogenic control of resistance and capacitance vessels in cat skeletal muscle. J Cardiovasc Pharmacol 12:413-422, 1988.
100. 2+ antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care 14(10):911-914, 1991.
101. Cost to pharmacists for 1 year's/day's treatment, according to January 1996 Average Wholesale Price (AWP) listed in Medi-Span® Prescription Pricing Guide, Medi-Span, Inc., Indianapolis, IN.